Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.

Journal article

Olsalazine and sulphasalazine were compared in a double-blind, double-dummy trial in the prevention of relapse of ulcerative colitis over 6 months. The majority were taking sulphasalazine. They were randomized to receive either olsalazine, 500 mg b.d., or sulphasalazine, 1 g b.d. Of 82 patients, 16 relapsed on olsalazine compared with 10 of 82 on sulphasalazine. This difference was not statistically significant (p = 0.16). Twenty-one patients reported adverse events in the olsalazine group, of whom 16 were withdrawn, while 20 patients reported adverse events in the sulphasalazine group, with 9 of them being withdrawn. The differences were not statistically significant. No major haematological or biochemical abnormalities occurred. Thus, olsalazine is similar to sulphasalazine for the prevention of relapse of ulcerative colitis.

Authors: Jewell, D; Ireland, A

• Publication status: Published
• Publisher: Informa Healthcare
• Journal: Scandinavian journal of gastroenterology. Supplement
• Volume: 148
• Issue: S148
• Pages: 45-47
• Publication date: 1988-01-01
• DOI: 10.3109/00365528809101547
• EISSN: 1751-1895
• ISSN: 0085-5928
• Language: English
• Keywords: Colitis, Ulcerative; Female; Random Allocation; Middle Aged; Aminosalicylic Acids; Male; Sulfasalazine; Double-Blind Method; Clinical Trials as Topic; Humans; Time Factors; Recurrence